Identification of SLAMF7 as an immune-related biomarker associated with the tumor microenvironment in colon adenocarcinoma using multi-omics and single-cell analyses

Abstract Objective To investigate the expression profiles, clinical implications, and tumor immunoregulatory roles of signaling lymphocyte activation molecule family member 7 (SLAMF7) in colon adenocarcinoma (COAD) using multi-omics data combined with clinical sample validation, thereby providing theoretical evidence for the identification of immune biomarkers for COAD. Methods Transcriptomic, clinicopathological, and mutation datasets for COAD were retrieved from the TCGA and GEO databases. Eighteen pairs of colon cancer tissues and matched adjacent non-tumorous tissues were collected from our hospital, and quantitative real-time PCR (qRT-PCR) was performed to detect SLAMF7 mRNA expression. Bioinformatic analyses were conducted to evaluate the associations between SLAMF7 expression and clinicopathological features, as well as patient prognosis. Receiver operating characteristic (ROC) curves and a prognostic nomogram were constructed. Differentially expressed gene (DEG) screening, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) were performed. The cBioPortal and MEXPRESS platforms were used to analyze gene mutation and DNA methylation profiles. The GSCA platform was applied to assess immune cell infiltration and drug sensitivity, and the TISCH database was utilized to identify the cellular origin of SLAMF7 at the single-cell level. Results SLAMF7 was significantly downregulated in COAD tumor tissues, a finding validated by multiple GEO datasets and clinical qRT-PCR results. Low SLAMF7 expression correlated with advanced TNM stage and distant metastasis. Patients with high SLAMF7 expression exhibited longer overall survival (OS) and disease-free interval (DFI); however, SLAMF7 was not an independent prognostic factor for OS in COAD patients. The nomogram demonstrated favorable performance in predicting 1-year and 3-year survival probabilities. Samples with high SLAMF7 expression were enriched in multiple anti-tumor immune pathways. SLAMF7 expression was positively correlated with the infiltration abundance of cytotoxic T cells and natural killer (NK) cells and was co-expressed with multiple immune checkpoint genes. Single-cell analyses demonstrated that SLAMF7 was predominantly expressed in tumor-infiltrating CD8 + T cells and NK cells, whereas malignant tumor cells barely expressed SLAMF7. SLAMF7 exhibited a low mutation frequency in COAD, and DNA methylation was not the primary mechanism underlying its downregulation. Furthermore, SLAMF7 expression was significantly associated with sensitivity to multiple chemotherapeutic and targeted agents. Conclusions SLAMF7 is downregulated in colon adenocarcinoma and reflects the magnitude of anti-tumor immune infiltration in tumor tissues, serving as a potential biomarker for evaluating the immune microenvironment status of COAD.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-13
DOI
https://doi.org/10.21203/rs.3.rs-11320746/v1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Identification of SLAMF7 as an immune-related biomarker associated with the tumor microenvironment in colon adenocarcinoma using multi-omics and single-cell analyses

Xiaobo Wei, Linyao Cheng, Jingmao Lao, WEI DENG et al.
2 links
Research Square
Cancer Immunotherapy and Biomarkers
preprint

Identification of SLAMF7 as an immune-related biomarker associated with the tumor microenvironment in colon adenocarcinoma using multi-omics and single-cell analyses

Xiaobo Wei, Linyao Cheng, Jingmao Lao, WEI DENG, GUANG LIU, YIBANG LAO
preprint en

Abstract

Abstract Objective To investigate the expression profiles, clinical implications, and tumor immunoregulatory roles of signaling lymphocyte activation molecule family member 7 (SLAMF7) in colon adenocarcinoma (COAD) using multi-omics data combined with clinical sample validation, thereby providing theoretical evidence for the identification of immune biomarkers for COAD. Methods Transcriptomic, clinicopathological, and mutation datasets for COAD were retrieved from the TCGA and GEO databases. Eighteen pairs of colon cancer tissues and matched adjacent non-tumorous tissues were collected from our hospital, and quantitative real-time PCR (qRT-PCR) was performed to detect SLAMF7 mRNA expression. Bioinformatic analyses were conducted to evaluate the associations between SLAMF7 expression and clinicopathological features, as well as patient prognosis. Receiver operating characteristic (ROC) curves and a prognostic nomogram were constructed. Differentially expressed gene (DEG) screening, Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and Gene Set Enrichment Analysis (GSEA) were performed. The cBioPortal and MEXPRESS platforms were used to analyze gene mutation and DNA methylation profiles. The GSCA platform was applied to assess immune cell infiltration and drug sensitivity, and the TISCH database was utilized to identify the cellular origin of SLAMF7 at the single-cell level. Results SLAMF7 was significantly downregulated in COAD tumor tissues, a finding validated by multiple GEO datasets and clinical qRT-PCR results. Low SLAMF7 expression correlated with advanced TNM stage and distant metastasis. Patients with high SLAMF7 expression exhibited longer overall survival (OS) and disease-free interval (DFI); however, SLAMF7 was not an independent prognostic factor for OS in COAD patients. The nomogram demonstrated favorable performance in predicting 1-year and 3-year survival probabilities. Samples with high SLAMF7 expression were enriched in multiple anti-tumor immune pathways. SLAMF7 expression was positively correlated with the infiltration abundance of cytotoxic T cells and natural killer (NK) cells and was co-expressed with multiple immune checkpoint genes. Single-cell analyses demonstrated that SLAMF7 was predominantly expressed in tumor-infiltrating CD8 + T cells and NK cells, whereas malignant tumor cells barely expressed SLAMF7. SLAMF7 exhibited a low mutation frequency in COAD, and DNA methylation was not the primary mechanism underlying its downregulation. Furthermore, SLAMF7 expression was significantly associated with sensitivity to multiple chemotherapeutic and targeted agents. Conclusions SLAMF7 is downregulated in colon adenocarcinoma and reflects the magnitude of anti-tumor immune infiltration in tumor tissues, serving as a potential biomarker for evaluating the immune microenvironment status of COAD.

Research Square
Guangxi Medical University (CN), Tumor Hospital of Guangxi Medical University (CN)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon